← Back to Search

Imaging Device

Ultrasound vs Veinviewer for Difficult IV Access

N/A
Waitlist Available
Led By Quincy Tran, MD, PhD
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who request Ultrasound guided peripheral IV (USGPIV)
Patients who are oriented to self (correct last name, first name), place (correct name of hospital), time (correct day of week or month of year) and person (correct name of current president)
Must not have
Patients with hemodynamically instability requiring rapid central access
Patients under 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40 minutes
Awards & highlights

Summary

This trial will compare the ultrasound machine and the Vein Viewer, a near-infrared device, to see which is more efficient in helping patients with difficult intravenous access in emergency departments.

Who is the study for?
This trial is for patients who have trouble getting IVs placed because their veins are hard to see or feel. They must be able to identify themselves, the hospital, the date, and the current president. Only English speakers who can consent and aren't intoxicated or confused can join.Check my eligibility
What is being tested?
The study compares two devices used to help insert IVs in difficult cases: an ultrasound machine (Zonare) and a near-infrared device called Veinviewer. It aims to find out which one is more efficient in an emergency department setting.See study design
What are the potential side effects?
There may not be direct side effects from using Zonare or Veinviewer as they are non-invasive imaging technologies; however, discomfort or complications related to multiple attempts at IV insertion might occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am asking for an ultrasound-guided IV.
Select...
I know my name, where I am, the date, and the current president.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I need immediate medical intervention due to unstable blood pressure or heart rate.
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 40 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Operator's time
Secondary outcome measures
Cannulation time
ED length of stay
IV size
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: ZonareExperimental Treatment1 Intervention
108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
Group II: VeinviewerExperimental Treatment1 Intervention
108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Veinviewer
2010
Completed Phase 4
~400

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
695 Previous Clinical Trials
376,815 Total Patients Enrolled
Quincy Tran, MD, PhDPrincipal Investigator - University of Maryland
University of Maryland, College Park

Media Library

Veinviewer (Imaging Device) Clinical Trial Eligibility Overview. Trial Name: NCT02618252 — N/A
Vascular Access Complications Research Study Groups: Veinviewer, Zonare
Vascular Access Complications Clinical Trial 2023: Veinviewer Highlights & Side Effects. Trial Name: NCT02618252 — N/A
Veinviewer (Imaging Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02618252 — N/A
~33 spots leftby Dec 2025